<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences</h1>
  <ul>
<li>In September 2025, an additional analysis included longer-term follow-up of Western patients (median follow-up time of Western patients of 13.7 months).</li>
<li>4.4 months, respectively.</li>
<li>placebo plus chemotherapy was 6.8 months vs.</li>
<li>(NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer (WCLC).</li>
<li>The statistical analysis plan for the study required a p-value of 0.0448 to achieve statistical significance.</li>
<li>Median overall survival was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy.</li>
<li>Data showed a hazard ratio consistent with the primary analysis was observed with an improved nominal p-value (HR=0.78; nominal p=0.0332).</li>
</ul>
<p><a href="https://finance.yahoo.com/news/summit-therapeutics-lung-cancer-drug-122807408.html">Source</a> · 2025-09-08T12:28:07+00:00</p>
</body>
</html>